Marlio Charles Mosseri has bought NVCT on 21 days since Jun 2023
10% owner at Nuvectis Pharma, Inc.
SEC CIK 0001806384 · Filings on SEC.gov ↗
Marlio Charles Mosseri's record
3 months after each buy, from the first price a copier could get.
20 buys since 2023 with 3 months of prices.
Every filing
21 filings since Jun 2023, newest first
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
Nuvectis Pharma, Inc.
10% owner
About Marlio Charles Mosseri
Marlio Charles Mosseri is a prominent biotech investor and former pharmaceutical executive recognized as a 10% owner of Nuvectis Pharma, Inc. (NVCT).( He has demonstrated significant commitment through extensive insider purchases, including 33,442 shares on June 18, 2025, for $269,543, 240,000 shares on February 7, 2025, for $1,200,000, and a total of 23 buys with no sells over five years, holding 2,976,203 shares valued at over $24 million as of mid-2025.(
Mosseri's ownership reflects strategic accumulation in the oncology-focused biotech firm, with his mailing address listed in London, UK.( While specific career highlights and education details are limited in public records, his status as a key shareholder alongside executives like Chairman & CEO Ron Bentsur underscores his influence in the sector.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.